Isofol Medical AB (publ) announced that the company has appointed Magnus Hurst as new Chief Financial Officer. He has broad financial experience and takes up the position with immediate effect. Magnus Hurst has long experience in financial roles at companies such as SAS and within the Kinnevik Group.

He currently holds a position as CFO and Head of Investor Relations at the biotech company Synartro and will combine this role with the new assignment as CFO at Isofol. Magnus holds an M.Sc. in Finance from Bayes Business School, UK, as well as a B.Sc.

in Business Studies and an LL.M from Uppsala University, Sweden. Magnus Hurst succeeds Roy Jonebrant, who has been acting CFO on a consultacy basis since March 2023 and whose contract expires at the end of January 2024.